COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every Friday

Methods

Variants of concern

RCTs

Treatment comparisons

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04470427
ModernaTX
Baden LR, N Engl J Med, 2020
COVE

Full text
Commentary
RNA based vaccine

mRNA-1273

Placebo

RCT
Phase 3
Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US N=30420
Some concerns
Details

Full description

NCT04860739, EudraCT2021-001978-37
Pfizer/BioNTech + Fosun Pharma
Borobia A M, Lancet, 2021

Full text
Commentary
RNA based vaccine

BNT162b2

No vaccine

RCT
Phase 2
Healthy, or clinically stable, adults (aged ≥18 and ≤60) that were SARS-COV-2 infection free and who had received a prime ChAdOx1-S vaccination between 8 and 12 weeks before the screening visit in 5 centers in Spain. N=676
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech + Fosun Pharma
Frenck R, N Engl J Med, 2021

Full text
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 3
Adolescents aged 12 to 15 years with no previous Covid-19 diagnosis or SARS-CoV-2 infection in 29 centers in the USA N=2264
Some concerns
Details

Full description

ChiCTR2000034825 ; NCT04523571
BioNTech RNA Pharmaceuticals
Li J, Nature Medicine, 2021

Full text
Commentary
RNA based vaccine

BNT162b1 10 mcg

BNT162b1 10 mcg

RCT
Phase 1
Healthy young adults between 18 and 55 years of age, and older adults between 65 and 85 that were SARS-COVID-2 infection-free at a single center in China. N=144
Low
Details

Full description

ISRCTN69254139, EudraCT: 2020-005085-33
AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma
Liu X, SSRN, 2021
Com-COV

Full text
Commentary
Commentary
Commentary
Commentary
RNA based vaccine

ChAd/ChAd-28

BNT/BNT-28

ChAd/BNT-28

BNT/ChAd-28

RCT
Phase 2
Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK N=463
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech + Fosun Pharma
Polack F, N Engl J Med, 2020

Full text
Commentary
; Commentary
; Commentary
; Commentary
; Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2/3
Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA N=43448
Some concerns
Details

Full description

NCT04368728
BioNTech SE, Pfizer
Walsh E, N Engl J Med, 2020

Full text
Commentary
RNA based vaccine

BNT162b1 10 mcg D1/21

BNT162b1 20 mcg D1/21

BNT162b1 30 mcg D1/21

BNT162b1 100 mcg D1/21

BNT162b2 10 mcg D1/21

BNT162b2 20 mcg D1/21

BNT162b2 30 mcg D1/21

BNT162b1 30 mcg D1/21

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA N=195
Low
Details

Full description

NCT04523571 ; ChiCTR
BioNTech / Pfizer / Fosun Pharma
Zhu F, ResearchSquare, 2021

Full text
Commentary
; Commentary
RNA based vaccine

BNT126b1 10 mcg/0.5 ml 2-

BNT126b1 30 mcg/0.5 ml 2-

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 and 65-85 at a single center in China N=144
Some concerns
Details

Full description